605199 Hainan Huluwa Pharmaceutical Group
- 9.59
- +0.33+3.56%
Hainan Huluwa Pharmaceutical Group News
Hainan Huluwa Pharmaceutical Group Bronchitis Inhaler Gets NMPA's Approval for Clinical Trials
Hainan Huluwa Pharmaceutical Group (605199.SH): The clinical trial approval notice for Afutelow inhalation solution of tartaric acid has been obtained.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced on July 23 that it has recently received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration for Afutroline tartrate inhalation solution, allowing clinical trials of the drug to proceed. Afutroline tartrate inhalation solution is suitable for the long-term treatment of bronchial constriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Hainan Huluwa Pharmaceutical Get China Nod for Hepatitis B Treatment
Express News | Fenuwa: Obtained drug registration certificate for propofol fumarate tenofovir tablets
Hainan Huluwa Pharmaceutical Group (605199.SH): There is no medicine to treat adenovirus.
On July 12, Gelunhui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) stated on the investor interaction platform that the company does not have drugs to treat adenovirus.
Express News | Hainan Huluwa Pharmaceutical Group: Omeprazole Enteric Capsules Pass Generic Drug Consistency Evaluation
Hainan Huluwa Pharmaceutical Group (605199.SH) will declare a cash dividend of CNY0.125 per share for the fiscal year 2023, with the registration date on July 15th.
Zhongtong Finance APP news, Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company will implement annual equity distribution in 2023, with a cash dividend of 0.125 yuan per share (including tax) and a record date of July 15th.
Huluwa Pharmaceutical Gets Nod to Market Asthma Drug for Kids
Hainan Huluwa Pharmaceutical Group (605199.SH) has obtained the registration certificate of Montelukast Sodium Chewable Tablets.
On June 18th, Gelonhui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Montelukast Sodium Chewable Tablets. Montelukast sodium chewable tablets are used for the prevention and long-term treatment of asthma in children aged 2-14, including the prevention of daytime and nighttime asthma symptoms, the treatment of aspirin-sensitive asthma patients, the prevention of exercise-induced bronchoconstriction, and the relief of symptoms caused by allergic rhinitis (seasonal and perennial allergic rhinitis in children aged 2-14).
Hainan Huluwa Pharmaceutical Group (605199.SH): Received notice of compliance inspection for pharmaceutical GMP.
On ****, Gelon Hui reported that Hainan Huluwa Pharmaceutical Group(605199.SH) recently received the drug GMP compliance inspection notice issued by the Hainan Provincial Drug Administration. This GMP compliance inspection marks the first time that the production workshops and production lines of the newly built Meian intelligent manufacturing base related to the company have passed the GMP compliance inspection. This indicates that the above-mentioned production workshops and production lines of the production base meet the requirements of drug GMP, which will be conducive to the company to continue to maintain stable product quality and production capacity to meet market demand.
Huluwa (605199.SH): Received a government subsidy of 16.209 million yuan
Gelonghui, May 30丨Huluwa (605199.SH) announced that from May 28, 2024 to the date of this announcement, the company and its subsidiaries received a total of RMB 16,209,443.35 (unaudited) of government subsidies related to revenue, accounting for 15.22% of the company's net profit attributable to owners of the parent company in 2023.
Hulu Wa (605199.SH): Received a government subsidy of 14.2998 million yuan
Gelonghui, May 27丨Huluwa (605199.SH) announced that from January 1, 2024 to the date of this announcement, the company and its subsidiaries received a total of RMB 14,299,792.79 (unaudited) of government subsidies relating to revenue, accounting for 13.43% of the company's net profit attributable to owners of the parent company in 2023.
Gourd Wa (605199.SH): No synthetic biological products or technical reserves
Gelonghui, May 14, 丨 Huluwa (605199.SH) said on the investor interactive platform that the company obtained the “Drug Registration Certificate” for terbutaline sulfate atomized inhalation solution approved and issued by the State Drug Administration on April 23, 2024, and has not yet been sold. There are currently no synthetic biological products or technology reserves.
Huluwa Pharmaceutical Gets Nod to Register Two Drugs
Express News | Fenuwa: Bromhexine hydrochloride injection and desloratadine tablets obtained drug registration certificates
Huluwa (605199.SH): Obtaining a drug registration certificate
On April 30, Gelonghui (605199.SH) announced that it has recently received “Drug Registration Certificates” for bromhexine hydrochloride injections and desloratadine tablets approved and issued by the State Drug Administration respectively.
Express News | Huluwa: Net revenue and profit both increased in 2023, and the cash dividend ratio reached 46.96%
Huluwa (605199.SH) announced its 2023 annual results, and net profit of 106 million yuan increased 24.29% year over year
Huluwa (605199.SH) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 1,905 billion yuan, an increase of 25.75%; net profit attributable to shareholders of listed companies was 106 million yuan, up 24.29% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 81.8068 million yuan, an increase of 20.21% year on year; basic earnings per share were 0.27 yuan. The company plans to distribute a cash dividend of 1.25 yuan (tax included) to all shareholders for every 10 shares.
Huluwa Pharma Gets Nod to Market Terbutaline Sulfate Inhaler
Huluwa (605199.SH): Obtained drug registration certificate for terbutaline sulfate nebulized inhalation solution
Gelonghui, April 23丨Huluwa (605199.SH) announced that the company recently received the “Drug Registration Certificate” for terbutaline sulfate nebulized inhalation solution approved and issued by the State Drug Administration. Terbutaline sulfate nebulized inhalation solution is used to relieve bronchospasm associated with bronchial asthma, chronic bronchitis, emphysema, and other lung diseases. Suitable for adults and children.
Analysis
Price Target
No Data
